Hypertension Diagnostics Begins Direct-to-Consumer Offering of its CVProfilor® DO-2020 System in U.S.

HealthCheck Screening to Offer the CVProfile™ Test in its Community Screening Programs

ST. PAUL, MNJune 26, 2002 – Hypertension Diagnostics, Inc. (Nasdaq SmallCap: HDII), announced today that its CVProfilor® DO-2020 System will become part of HealthCheck Screening, a non-profit community outreach screening program. HealthCheck is headquartered in Lake Oswego, Oregon, and partners with the local American Stroke Association and the American Heart Association to conduct health screening programs.

 

     
HealthCheck is the leading consumer-direct mobile health screening company in the Pacific Northwest offering three vascular tests, osteoporosis testing as well as cholesterol, glucose and liver function blood tests which are all CLIA (Clinical Laboratory Improvement Amendments) approved. Through education and affordable non-invasive screenings, HealthCheck’s goal is to increase awareness about cardiovascular disease and the steps that an individual can take to determine their risk levels, without a referral from a physician. HealthCheck’s screening tests are offered at a variety of venues including churches, community centers, senior centers and athletic clubs as well as through corporate screenings.

“The CVProfilor® System is a great addition to our health programs since it screens for underlying vascular disease at an early age. An average of 15% of all participants screened have a vascular abnormality of some sort which will result in lifestyle modification or other therapeutic intervention, and we encourage all participants to share their results with a physician,” said Sheila Goudge, President of HealthCheck Screening, Inc. “Typically, people associate cardiovascular disease with such phrases as: ‘it can’t happen to me’, ‘I am not old enough’, or ‘strokes are for older people’, and when our society continues to see younger people such as 33 year-old St. Louis Cardinals pitcher Darryl Kile experiencing a cardiovascular event, we understand the value of health screening programs and preventative tests. The word needs to get out to people at a younger age that there are tests one can take to determine risk levels for cardiovascular disease. Our new relationship with Hypertension Diagnostics, Inc. is important as the CVProfilor® System completes the vascular platform of tests that we offer. It is the only FDA cleared device that measures the elasticity of both large and small arteries and it can detect potential underlying cardiovascular disease much earlier than other tests currently available,” added Goudge.

Greg H. Guettler, President of Hypertension Diagnostics, Inc., commented that, “Our experience at national and regional tradeshows, where we have had continuous lines at our exhibit booth for the CVProfile™ Test, is a good indication of consumer interest. Cardiovascular disease costs Americans an estimated $320 billion a year, the majority of which is spent on coronary artery and heart disease. In spite of these enormous expenditures, one in four persons who die from cardiovascular related diseases experienced no advance symptoms. The best way to address this problem is for all of us to take control over evaluating our health risks before we suffer the devastating effects of cardiovascular disease. We should obtain the appropriate information which allows us to make educated and responsible decisions about our health (as opposed to disease) and thereby live longer, healthier lives. Numerous studies point to the overwhelming health and economic benefits associated with managing one’s health through proactive, preventative and screening measures. Hypertension Diagnostics, Inc. looks forward to a mutually beneficial screening program with HealthCheck as well as providing individuals with the first step toward living a longer and healthier life.”
 
Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated.

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
  
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Investor Relations: Jens Dalsgaard and Tony Altavilla,
Managing Directors
Redwood Consultants, LLC
Mill Valley, CA 94941
415-380-0500

Contact: Greg H. Guettler, President

Return to the Main HDI Newsroom

   

Back to Top

 

 

     

Copyright © 2009 Hypertension Diagnostics, Inc
Last revised Wednesday February 11, 2009
HDI Legal Information